13F filer · CIK 1587114
EcoR1 Capital, LLC
San Francisco, CA · filing since Q4 2014 · last filing Aug 14, 2026
Reported value
$2.1B
$-299.6M vs prior
Positions
33
New / sold out
11 / 8
Added / reduced
3 / 4
Turnover
11.8%
buys $261.0M · sells $831.6M
Top-10 weight
86.3%
Biggest buys vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| New | FIRST TRACKS BIOTHERAPEUTICS | +3,174,519 | – | +$63.9M |
| New | CG ONCOLOGY INCCALL | +561,500 | – | +$39.9M |
| Added | CG ONCOLOGY INC | +392,300 | +35.6% | +$27.9M |
| New | FULCRUM THERAPEUTICS INC | +6,549,866 | – | +$24.0M |
| New | LEGEND BIOTECH CORP | +800,000 | – | +$23.1M |
| Added | STOKE THERAPEUTICS INC | +635,000 | +635.0% | +$20.8M |
| Added | ATARA BIOTHERAPEUTICS INC | +1,452,407 | +1458.3% | +$16.7M |
| New | AURA BIOSCIENCES INC | +1,666,667 | – | +$11.8M |
| New | ODYSSEY THERAPEUTICS INC | +555,555 | – | +$10.4M |
| New | PHARVARIS N V | +235,000 | – | +$8.1M |
4 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Biggest sells vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Sold out | JAZZ PHARMACEUTICALS PLC | -1,706,469 | -100.0% | $-322.6M |
| Sold out | CENTESSA PHARMACEUTICALS PLC | -6,000,000 | -100.0% | $-238.3M |
| Sold out | CRINETICS PHARMACEUTICALS IN | -4,288,120 | -100.0% | $-155.7M |
| Sold out | XENCOR INC | -2,183,000 | -100.0% | $-26.3M |
| Reduced | RELAY THERAPEUTICS INC | -1,206,814 | -63.4% | $-22.6M |
| Reduced | MBX BIOSCIENCES INC | -388,500 | -50.0% | $-21.4M |
| Sold out | CENTESSA PHARMACEUTICALS PLCCALL | -410,800 | -100.0% | $-16.3M |
| Reduced | ERASCA INC | -570,000 | -63.3% | $-10.4M |
| Sold out | REPLIMUNE GROUP INC | -1,000,000 | -100.0% | $-7.7M |
| Reduced | MEREO BIOPHARMA GROUP PLC | -12,368,855 | -92.5% | $-3.9M |
2 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.
Reported value by quarter
Holdings · Q2 2026
| # | Security | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | ZYMEWORKS INCCOM | 22,970,388 | $600.4M | 29.19% |
| 2 | ANAPTYSBIO INCCOM | 7,880,094 | $531.9M | 25.86% |
| 3 | AKTIS ONCOLOGY INCCOM | 4,824,469 | $155.5M | 7.56% |
| 4 | CG ONCOLOGY INCCOM | 1,494,300 | $106.2M | 5.16% |
| 5 | ETON PHARMACEUTICALS INCCOM | 2,171,938 | $78.6M | 3.82% |
| 6 | CRISPR THERAPEUTICS AGNAMEN AKT | 1,389,276 | $75.8M | 3.68% |
| 7 | ORIC PHARMACEUTICALS INCCOM | 6,728,116 | $72.9M | 3.54% |
| 8 | FIRST TRACKS BIOTHERAPEUTICSORD SHS ADDED | 3,174,519 | $63.9M | 3.11% |
| 9 | LAKEFRONT BIOTHERAPEUTICS NVSPON ADR | 1,667,119 | $50.0M | 2.43% |
| 10 | NEUROGENE INCCOM | 1,271,342 | $40.0M | 1.94% |
23 more rows. Subscribe for $29/month to see every row, download the data and use the API.